BlackRock’s Ionis Pharmaceuticals IONS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$849M Buy
10,704,660
+262,184
+3% +$19.7M 0.01% 862
2026
Q1
$784M Sell
10,442,476
-205,387
-2% -$16.2M 0.01% 820
2025
Q4
$842M Buy
10,647,863
+199,923
+2% +$15.1M 0.01% 770
2025
Q3
$684M Sell
10,447,940
-448,997
-4% -$21.9M 0.01% 883
2025
Q2
$431M Sell
10,896,937
-367,505
-3% -$12M 0.01% 1156
2025
Q1
$340M Sell
11,264,442
-401,106
-3% -$13.1M 0.01% 1265
2024
Q4
$408M Buy
11,665,548
+852,525
+8% +$31.9M 0.01% 1212
2024
Q3
$433M Buy
10,813,023
+491,993
+5% +$22.9M 0.01% 1181
2024
Q2
$492M Buy
10,321,030
+549,139
+6% +$22.5M 0.01% 1018
2024
Q1
$424M Buy
9,771,891
+714,361
+8% +$34.1M 0.01% 1151
2023
Q4
$458M Sell
9,057,530
-57,097
-0.6% -$2.73M 0.01% 1079
2023
Q3
$413M Sell
9,114,627
-21,547
-0.2% -$889K 0.01% 1034
2023
Q2
$375M Buy
9,136,174
+153,928
+2% +$5.92M 0.01% 1133
2023
Q1
$321M Sell
8,982,246
-97,311
-1% -$3.65M 0.01% 1218
2022
Q4
$343M Buy
9,079,557
+143,495
+2% +$6.04M 0.01% 1151
2022
Q3
$395M Buy
8,936,062
+104,672
+1% +$4.41M 0.01% 970
2022
Q2
$327M Buy
8,831,390
+387,547
+5% +$14.6M 0.01% 1159
2022
Q1
$313M Sell
8,443,843
-95,439
-1% -$3.12M 0.01% 1327
2021
Q4
$260M Buy
8,539,282
+419,429
+5% +$13.2M 0.01% 1539
2021
Q3
$272M Sell
8,119,853
-59,813
-0.7% -$2.25M 0.01% 1491
2021
Q2
$326M Sell
8,179,666
-1,628,896
-17% -$63.8M 0.01% 1408
2021
Q1
$441M Buy
9,808,562
+58,060
+0.6% +$3.24M 0.01% 1106
2020
Q4
$551M Buy
9,750,502
+1,285,095
+15% +$64M 0.02% 831
2020
Q3
$402M Sell
8,465,407
-185,321
-2% -$10.3M 0.01% 879
2020
Q2
$510M Buy
8,650,728
+482,788
+6% +$26.9M 0.02% 699
2020
Q1
$386M Sell
8,167,940
-234,449
-3% -$13.1M 0.02% 752
2019
Q4
$508M Buy
8,402,389
+51,590
+0.6% +$3.07M 0.02% 797
2019
Q3
$500M Sell
8,350,799
-451,777
-5% -$29.4M 0.02% 751
2019
Q2
$566M Buy
8,802,576
+1,181,004
+15% +$83.5M 0.02% 676
2019
Q1
$619M Sell
7,621,572
-54,685
-0.7% -$3.53M 0.03% 617
2018
Q4
$415M Buy
7,676,257
+213,000
+3% +$10.9M 0.02% 752
2018
Q3
$385M Buy
7,463,257
+408,678
+6% +$19.2M 0.02% 957
2018
Q2
$294M Buy
7,054,579
+124,233
+2% +$5.51M 0.01% 1128
2018
Q1
$305M Sell
6,930,346
-42,260
-0.6% -$2.15M 0.01% 1060
2017
Q4
$351M Sell
6,972,606
-30,885
-0.4% -$1.69M 0.02% 948
2017
Q3
$355M Buy
7,003,491
+179,504
+3% +$9.4M 0.02% 890
2017
Q2
$347M Buy
6,823,987
+264,179
+4% +$12.3M 0.02% 869
2017
Q1
$264M Buy
6,559,808
+6,542,394
+37,570% +$294M 0.01% 1066
2016
Q4
$833K Sell
17,414
-1,541
-8% -$61K ﹤0.01% 1552
2016
Q3
$695K Sell
18,955
-82,238
-81% -$2.57M ﹤0.01% 1626
2016
Q2
$2.36M Sell
101,193
-75,463
-43% -$2.43M ﹤0.01% 1095
2016
Q1
$7.16M Sell
176,656
-10,553
-6% -$429K 0.01% 770
2015
Q4
$11.6M Buy
187,209
+63,388
+51% +$3.42M 0.02% 646
2015
Q3
$5M Sell
123,821
-34,154
-22% -$1.77M 0.01% 784
2015
Q2
$9.09M Sell
157,975
-113,103
-42% -$7.19M 0.01% 691
2015
Q1
$17.3M Buy
271,078
+114,013
+73% +$7.74M 0.02% 557
2014
Q4
$9.7M Buy
157,065
+153,700
+4,568% +$7.58M 0.01% 682
2014
Q3
$130K Sell
3,365
-1,570
-32% -$55.6K ﹤0.01% 1639
2014
Q2
$170K Sell
4,935
-78,545
-94% -$2.47M ﹤0.01% 1575
2014
Q1
$3.61M Sell
83,480
-37,444
-31% -$1.82M 0.01% 912
2013
Q4
$4.82M Buy
120,924
+117,387
+3,319% +$4.18M 0.01% 841
2013
Q3
$133K Hold
3,537
﹤0.01% 1594
2013
Q2
$95K Buy
+3,537
New +$75.2K ﹤0.01% 1677

Other funds holding IONS

BlackRock's IONS Position: Q2 2026 in Review

BlackRock increased its Ionis Pharmaceuticals (IONS) stake by 2.5% in Q2 2026, buying an estimated $19.7M and bringing the position to 10,704,660 shares worth $849M. The position accounts for 0.01% of the portfolio, ranked #862.

BlackRock first reported a position in IONS in Q2 2013 and has held it in 53 quarters since. 513 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • BlackRock held 10,704,660 shares of Ionis Pharmaceuticals worth $849M as of Q2 2026.
  • BlackRock bought 262,184 Ionis Pharmaceuticals shares in Q2 2026, an estimated $19.7M.
  • Ionis Pharmaceuticals made up 0.01% of BlackRock's portfolio in Q2 2026, its #862 holding.
  • BlackRock first reported a position in Ionis Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • 513 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.